REG - Avacta Group PLC - Result of Annual General Meeting <Origin Href="QuoteRef">AVTG.L</Origin>

AvactaAnnouncement

18/01/2018 11:30

RNS Number : 2759C
Avacta Group PLC
18 January 2018
18 January 2018
Avacta Group plc
("Avacta", "the Group" or "the Company")
Result of Annual General Meeting
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
The full text of each resolution is set out in the Notice of Annual General Meeting, included in the 2017 Annual Report, which is available on the Company's website www.avacta.com.
- Ends -
For further information from Avacta Group plc, please contact:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Tel: +44 (0) 844 414 0452
www.avacta.com
finnCap Ltd
Geoff Nash / Giles Rolls - Nominated Adviser
Tim Redfern / Alice Lane / Nikita Jain - Corporate Broking
WG Partners
Nigel Birks / Nigel Barnes
David Wilson / Claes Spang
Tel: +44 (0) 207 220 0500
www.finncap.com
Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
www.wgpartners.co.uk
Zyme Communications (Trade and Regional Media)
Katie Odgaard
Yellow Jersey PR (Financial Media and IR)
Sarah Hollins
Tel: +44 (0)7787 502 947
katie.odgaard@zymecommunications.com 
Tel: +44 (0)7764 947137
avacta@yellowjerseypr.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets. 
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RAGGGUCPGUPRGGR